CYP2C9基因多态性与临床个体化用药  

Gene polymorphism of CYP2C9 and clinical individualized drug therapy

作　　者：陈灵 王健[2] 李居怡 邹吉利 吴金虎 

机构地区：[1]武汉市第三医院药学部,武汉430060 [2]宁夏回族自治区人民医院药剂科,银川750021

出　　处：《国际药学研究杂志》2012年第6期493-497,共5页Journal of International Pharmaceutical Research

基　　金：宁夏自然科学基金项目(NZ07109);宁夏卫生厅重点科研课题(W200707)

摘　　要：细胞色素P450酶(CYP)2C9是人类肝中一种重要的药物代谢酶,参与多种内、外源物质(包括约10%临床药物)的代谢。CYP2C9基因具有高度多态性,迄今为止新发现并已被命名的有30个等位基因。基因多态性的存在可导致CYP2C9酶的活性发生改变,从而使相关药物的代谢特性发生改变,可能导致药物临床疗效和副作用的不同。本文主要对CYP2C9基因多态性及其对药物代谢的影响,以及相关临床个体化治疗的研究进展进行综述。Cytochrome P450（CYP） 2C9 is an essential human liver enzyme for drug metabolism,and plays and important role in many endogenous and exogenous substances metabolism,including 10% of clinical medicine.CYP2C9 has a high genetic polymorphism,so far 30 alleles have been identified.Mutations in genes may alter the activity of CYP2C9,leading to the change of metabolism rate and elimination rate of related drugs and the increasing the risk of drug adverse effects or toxicity.This article reviews the genetic polymorphism of CYP2C9 and its effect on drug metabolism,and summarizes the research advances of related individualized treatment.

关 键 词：CYP2C9 多态性 个体化用药 

分 类 号：R96[医药卫生—药理学]